Status:
RECRUITING
Study of the Link Between Complement Activation and IgA Nephropathy Severity
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
IgA Nephropathy Severity in Kidney Transplantation
Eligibility:
All Genders
18+ years
Brief Summary
ICONE study (IgA Complement and NEphropathy is a prospective monocentric observational study. The main objective is to evaluate the relevance of complement activation as a biomarker of disease severi...
Detailed Description
IgA nephropathy (IgAN) is a common cause of glomerulonephritis and a major cause of end stage renal disease in up to 20-40% of patients. However, its prognosis still cannot be accurately predicted due...
Eligibility Criteria
Inclusion
- Adult patients, male or female, with a biopsy proven IgA nephropathy.
- Primitive and secondary forms can be included
- Regardless of the date of diagnosis and the level of kidney function
- With or without past of kidney transplantation
- Followed in the Nephrology Department, Strasbourg University Hospital
- Signed informed consent
Exclusion
- Active or recent infectious or inflammatory syndrome (\<2 months), recent vaccination (\<2 months), ongoing acute humoral rejection treatment, treatment with plasma exchanges (\<2 months), current treatment with complement inhibitors
- Impossibility of giving informed information (emergency situation, difficulties in understanding, etc.)
- Subject under safeguard of justice, guardianship or curatorship
Key Trial Info
Start Date :
May 9 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT05234463
Start Date
May 9 2022
End Date
May 1 2027
Last Update
August 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de néphrologie
Strasbourg, France